Selexis SA: Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody
Pandion will leverage Selexis proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases Selexis SA, a JSR Life Sciences company, announced today that it has signed a service agreement with Pandion Therapeutics, Inc., to advance the development of Pandion s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Under the terms of the agreement, Pandion will utilize Selexis proprietary SURE
technology Platform to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials. Pandion s selection of Selexis as a cell line development partner is a testament to the value of our SURE
News Category Global Banking & Finance Reviews
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
-Phase 1a trial achieved primary objective of safety and tolerability
-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases
-PT101 maintained selectivity for regulatory T cells at all doses tested
-Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021
-Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET